Literature DB >> 21569106

Manassantin A inhibits cAMP-induced melanin production by down-regulating the gene expressions of MITF and tyrosinase in melanocytes.

Hwa Dong Lee, Won-Hee Lee, Eunmiri Roh, Chang-Seob Seo, Jong-Keun Son, Seung Ho Lee, Bang Yeon Hwang, Sang-Hun Jung, Sang-Bae Han, Youngsoo Kim.   

Abstract

Microphthalmia-associated transcription factor (MITF) is inducible in response to cAMP through the cAMP-responsive element-binding protein (CREB) and plays a pivotal role in the melanocyte-specific expression of tyrosinase or tyrosinase-related proteins (TRPs) for melanin biosynthesis. Manassantin A from Saururus chinensis inhibits cAMP-induced melanin production in B16 melanoma cells. Here, we focused on molecular basis of the antimelanogenic activity. Manassantin A consistently inhibited the cAMP elevator 3-isobutyl-1-methylxanthine (IBMX)- or dibutyryl cAMP-induced melanin production in B16 cells or in melan-a melanocytes by down-regulating the expression of tyrosinase or TRP1 gene. Moreover, manassantin A suppressed MITF induction through IBMX-activated CREB pathway, directly inhibiting the Ser-133 phosphorylation of CREB. However, manassantin A did not affect IBMX-increased cAMP levels in these cells but also other cAMP-dependent melanogenic pathways through post-translational modifications of MITF. This putative molecular mechanism of manassantin A in the inhibition of melanin production suggests its pharmacological potential in skin hyperpigmentation.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569106     DOI: 10.1111/j.1600-0625.2011.01296.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  8 in total

1.  Discovery of Manassantin A Protein Targets Using Large-Scale Protein Folding and Stability Measurements.

Authors:  M Ariel Geer Wallace; Do-Yeon Kwon; Douglas H Weitzel; Chen-Ting Lee; Tesia N Stephenson; Jen-Tsan Chi; Robert A Mook; Mark W Dewhirst; Jiyong Hong; Michael C Fitzgerald
Journal:  J Proteome Res       Date:  2016-07-08       Impact factor: 4.466

2.  Two new lignans and melanogenesis inhibitors from Schisandra nigra.

Authors:  Yuji Narukawa; Chihiro Komatsu; Rina Yamauchi; Sakiko Shibayama; Mayuko Hachisuka; Fumiyuki Kiuchi
Journal:  J Nat Med       Date:  2016-05-03       Impact factor: 2.343

3.  A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth.

Authors:  Liwei Lang; Xiaoyu Liu; Yan Li; Qing Zhou; Ping Xie; Chunhong Yan; Xiaoguang Chen
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

4.  MiR-585-5p impedes gastric cancer proliferation and metastasis by orchestrating the interactions among CREB1, MAPK1 and MITF.

Authors:  Yunwei Wang; Ming Li; Jiaoxia Zeng; Yunshu Yang; Zengshan Li; Sijun Hu; Fangfang Yang; Na Wang; Wenlan Wang; Jun Tie
Journal:  Front Immunol       Date:  2022-10-04       Impact factor: 8.786

5.  Cellular Anti-Melanogenic Effects of a Euryale ferox Seed Extract Ethyl Acetate Fraction via the Lysosomal Degradation Machinery.

Authors:  Seung-Hwa Baek; In-Jeong Nam; Hyeong Seob Kwak; Ki-Chan Kim; Sang-Han Lee
Journal:  Int J Mol Sci       Date:  2015-04-23       Impact factor: 5.923

6.  The extract of Rhodobacter sphaeroides inhibits melanogenesis through the MEK/ERK signaling pathway.

Authors:  Wen-Sheng Liu; Yu-Diao Kuan; Kuo-Hsun Chiu; Wei-Kuang Wang; Fu-Hsin Chang; Chen-Hsun Liu; Che-Hsin Lee
Journal:  Mar Drugs       Date:  2013-06-03       Impact factor: 5.118

7.  The Extracts of Astragalus membranaceus Inhibit Melanogenesis through the ERK Signaling Pathway.

Authors:  Yu-Tzu Tsao; Chun-Yu Kuo; Yu-Diao Kuan; Han-Chen Lin; Li-Hsien Wu; Che-Hsin Lee
Journal:  Int J Med Sci       Date:  2017-09-03       Impact factor: 3.738

8.  A 2D and 3D melanogenesis model with human primary cells induced by tyrosine.

Authors:  Maryana S Branquinho; Maysa B Silva; Jacqueline C Silva; Maria C Sales; Silvia B Barros; Silvya S Maria-Engler; Ana Campa
Journal:  J Biol Methods       Date:  2020-07-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.